Tuesday, April 30, 2019
Dyadic International (DYAI)
Sub-Licensing Agreement Providing Optionality for C1 Technology.
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Announces significant licensing agreement. Australian based drug development and contract
manufacturing firm, Luina Bio, announced plans to utilize Dyadic’s C1 gene
expression technology platform for the development and commercialization of
biological products to prevent and treat animal diseases. This is the company’s
first sub-licensing agreement, which, we believe, validates the company’s
proprietary C1 technology. - Impressive list of partners. Luina Bio is the first licensing move for the company’s
technology and adds to a list of significant R&D partnerships with
pharmac…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.